{
  "id": "mhgap#risk_safety_9f64a98b",
  "content": "Further research would help to quantify the risks of\nanxiety and improved functioning in adults with\nlonger term use.\nanxiety disorders but also increased risk of adverse\neffects and dropout following benzodiazepine use.\nImplementation considerations\ny A strong recommendation was made despite low-\ny Benzodiazepines should not be universally\nquality evidence since the GDG concluded that the\nprescribed to treat anxiety or distress and should\nrisks of the intervention outweighed the benefits.\ninstead be used in select cases of acute and severe\nRemarks anxiety or distress and where other treatment\napproaches have proved ineffective or unavailable.\ny Benzodiazepines for panic disorder examined in\ny Before prescribing benzodiazepines, discuss the\nthe included reviews were alprazolam, adinazolam,\ntreatment options and any concerns the person has.\nclonazepam, diazepam and midazolam.\nExplain the rationale for prescribing this medicine\ny Benzodiazepines for GAD examined in the included\nand provide written and verbal information on\nreviews were not reported individually.\nbenefits and harms; side-effects; drug interactions;\ny Benzodiazepines have a risk of dependence. Use\nthe importance of taking medicines as prescribed;\nbeyond the recommended 3- to 7-day maximum\n25\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "stress",
      "study",
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety Further research would help to quantify the risks of\nanxiety and improved functioning in adults with\nlonger term use.\nanxiety disorders but also increased risk of adverse\neffects and dropout following benzodiazepine use.\nImplementation considerations\ny A strong recommendation was made despite low-\ny Benzodiazepines should not be universally\nquality evidence since the GDG concluded that the\nprescribed to treat anxiety or distress and should\nrisks of the intervention outweighed the benefits.\ninstead be used in select cases of acute and severe\nRemarks anxiety or distress and where other treatment\napproaches have proved ineffective or unavailable.\ny Benzodiazepines for panic disorder examined in\ny Before prescribing benzodiazepines, discuss the\nthe included reviews were alprazolam, adinazolam,\ntreatment options and any concerns the person has.\nclonazepam, diazepam and midazolam.\nExplain the rationale for prescribing this medicine\ny Benzodiazepines for GAD examined in the included\nand provide written and verbal information on\nreviews were not reported individually.\nbenefits and harms; side-effects; drug interactions;\ny Benzodiazepines have a risk of dependence. Use\nthe importance of taking medicines as prescribed;\nbeyond the recommended 3- to 7-day maximum\n25\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders Further research would help to quantify the risks of\nlo âu and improved functioning in adults with\nlonger term use. lo âu disorders but also increased nguy cơ of adverse\neffects and dropout following benzodiazepine use."
}